BioCritica Launches; Receives Investment

Eli Lilly and Company (NYSE:LLY), Care Capital, NovaQuest Capital formed BioCritica Inc., a Central Indiana-based biotechnology company.

BioCritica will initially focus on the continued U.S. development and commercialization of Xigris® (drotrecogin alfa (activated)), Lilly’s medicine for the treatment of severe sepsis. As part of a licensing agreement, the company will acquire the U.S. development and commercialization rights to Xigris and will also receive the rights to potentially acquire critical care compounds currently in pre-clinical development at Lilly. The collaboration also includes a supply agreement, a services agreement and an option for BioCritica to acquire the development and commercialization rights to Xigris outside the U.S. at a later date.
In return, Lilly will receive royalties on future U.S. sales of Xigris and will also receive an equity stake in BioCritica.

BioCritica is also developing a pipeline of other products.

The creation of the company, which is led by CEO David Broecker, received the support of the Indiana Economic Development Corporation (IEDC) and BioCrossroads.



Join the discussion